BioSpace News Archive

Extremity reconstruction implies the restoration of limbs and limb functions to patients who have suffered the removal of limbs due to trauma or medical removal after cancer or other issues.

Transparency Market Research has published a new report titled ‘Surgical Imaging Arms Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the new report, the global surgical imaging arms market was valued above US$ 1,000 Mn in 2017.

Transparency Market Research anticipates that the particle therapy market features fragmented vendor landscape owing to a large number of key players operating in the market.

Transparency Market Research has published a new report on the HIV/AIDS diagnostics market for the forecast period of 2019–2027.

Cancer is one of the leading causes of fatalities worldwide. Chimeric antigen receptor or CAR-T cell therapy comprises re-engineering of WBC or the white blood cells of the cancer-affected patient.

As a per a recent report added in the vast library of TMR Research the global glucose monitoring market is expected to witness a substantial growth during the tenure of 2019 to 2029.

Ryvu Therapeutics, a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, has signed a grant agreement with the National Centre for Research and Development for the development of targeted immuno-oncology therapy.

Lysogene, a Phase 3 gene therapy platform company targeting central nervous system diseases, announced that, following discussions with the U.S. Food and Drug Administration, a clinical hold was issued for the clinical trial AAVance, a global Phase 2/3 clinical trial of LYS-SAF302, a gene therapy for the treatment of Mucopolysaccharidosis Type IIIA

Baylx, Inc. announced that the U.S. Food and Drug Administration has cleared Baylx’s Investigational New Drug application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells product in patients with Rheumatoid Arthritis.

Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise.